Patents Represented by Attorney Samuel B. Rollins
-
Patent number: 8350039Abstract: The present invention is directed to substituted isoquinoline derivatives, pharmaceutically acceptable salts thereof, and tautomers of such compounds or salts, that inhibit ?-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which BACE is involved.Type: GrantFiled: August 22, 2011Date of Patent: January 8, 2013Assignee: High Point Pharmaceuticals, LLCInventors: Adnan M. M. Mjalli, Bapu Gaddam, Devi Reddy Gohimukkula, Dharma Rao Polisetti, Hassan El Abdellaoui, Mohan Rao, Pingzhen Wang, Robert Carl Andrews, Rongyuan Xie, Tan Ren
-
Patent number: 8344001Abstract: Compound of formula (I) wherein W, X, Y, Z is —C(R1)? or N; R1 is hydrogen or alkyl, V is N or C (i.e.Type: GrantFiled: May 19, 2008Date of Patent: January 1, 2013Assignee: High Point Pharmaceuticals, LLCInventors: Rolf Hohlweg, Jane Marie Lundbeck, Johannes Cornelis de Jong
-
Patent number: 8334305Abstract: Novel substituted amide inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.Type: GrantFiled: February 19, 2008Date of Patent: December 18, 2012Assignee: High Point Pharmaceuticals, LLCInventor: Soren Ebdrup
-
Patent number: 8329715Abstract: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-? or by PDE4, including but not limited to rheumatoid arthritis.Type: GrantFiled: March 2, 2012Date of Patent: December 11, 2012Assignee: High Point Pharmaceuticals, LLCInventors: Adnan M. M. Mjalli, Bapu Gaddam, Dharma Rao Polisetti, Matthew J. Kostura, Mustafa Guzel
-
Patent number: 8318927Abstract: 6-(4-Cyclopropylpiperazin-1-yl)-2?-methyl-[3,4?]bipyridinyl and salts and hydrates thereof interact with the histamine H3 receptor are defined.Type: GrantFiled: May 21, 2007Date of Patent: November 27, 2012Assignee: High Point Pharmaceuticals, LLCInventors: Jane Marie Lundbeck, Rolf Hohlweg
-
Patent number: 8217086Abstract: The present invention describes phenoxy-acetic acids and pharmaceutical compositions containing the same and methods of using the same. The phenoxy-acetic acids are activators of PPAR-? and should be useful for treating conditions mediated by the same.Type: GrantFiled: April 5, 2011Date of Patent: July 10, 2012Assignee: High Point Pharmaceuticals, LLCInventor: Soren Ebdrup
-
Patent number: 8153798Abstract: The use of substituted amides of structure (I) for modulating the activity of 11 ?-hydroxysteroid dehydrogenase type 1 (11 ?HSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11 ?HSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.Type: GrantFiled: March 9, 2007Date of Patent: April 10, 2012Assignee: High Point Pharmaceuticals, LLCInventors: John Paul Kilburn, Henrik Sune Andersen, Gita Camilla Tejlgaard Kampen
-
Patent number: 8138342Abstract: A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11 ?-hydroxy-Steroid dehydrogenase type 1 (11?HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g. the metabolic syndrome.Type: GrantFiled: October 12, 2005Date of Patent: March 20, 2012Assignee: High Point Pharmacueticals, LLCInventors: John Paul Kilburn, Henrik Sune Andersen, Gita Camilla Tejlgaard Kampen
-
Patent number: 8053598Abstract: Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPAR? subtype.Type: GrantFiled: May 3, 2005Date of Patent: November 8, 2011Assignee: High Point Pharmaceuticals, LLCInventor: Zdenék Polivka
-
Patent number: 8053447Abstract: A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11?-hydroxy-steroid dehydrogenase type 1 (11?HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g. the metabolic syndrome.Type: GrantFiled: March 27, 2007Date of Patent: November 8, 2011Assignee: High Point Pharmaceuticals, LLCInventors: Soren Ebdrup, Henrik Sune Andersen
-
Patent number: 8048908Abstract: The use of substituted amides for modulating the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, of the general formula I. Their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11?HSDI and may be useful in the treatment of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.Type: GrantFiled: June 28, 2007Date of Patent: November 1, 2011Assignee: High Point Pharmaceuticals, LLCInventors: Soren Ebdrup, Henrik Sune Andersen
-
Patent number: 7767695Abstract: A novel class of substituted piperidines, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.Type: GrantFiled: July 15, 2004Date of Patent: August 3, 2010Assignee: High Point Pharmaceuticals, LLCInventor: Florencio Zaragoza Dorwald
-
Patent number: 7723323Abstract: The use of fused 1,2,4-triazoles for modulating the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and the use of these compounds as pharmaceutical compositions has been described. Also a novel class of fused 1,2,4-triazoles, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments has been described. The present compounds are modulators and more specifically inhibitors of the activity of 11?HSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.Type: GrantFiled: February 27, 2008Date of Patent: May 25, 2010Assignee: High Point Pharmaceuticals, LLCInventors: Henrik Sune Andersen, Gita Camilla Tejlgaard Kampen, Inge Thoger Christensen, John Patrick Mogensen, Annette Rosendal Larsen
-
Patent number: 7709528Abstract: Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPAR? suptype.Type: GrantFiled: May 23, 2006Date of Patent: May 4, 2010Assignee: High Point Pharmaceuticals, LLCInventors: Lone Jeppesen, Ingrid Pettersson, Per Sauerberg, Pavel Pihera, Miroslav Havranek
-
Patent number: 7700583Abstract: A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11?-hydroxy-steroid dehydrogenase type 1 (11?HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g. the metabolic syndrome.Type: GrantFiled: October 6, 2005Date of Patent: April 20, 2010Assignee: High Point Pharmaceuticals, LLCInventors: Anette Gundertofte, Anker Steen Jorgensen, Gita Camilla Tejlgaard Kampen, Henrik Sune Andersen, Inge Thoger Christensen, Kilburn Paul John
-
Patent number: 7645791Abstract: Novel salicylic anilides are chemical uncouplers useful e.g. for the treatment of obesity.Type: GrantFiled: June 27, 2008Date of Patent: January 12, 2010Assignee: High Point Pharmaceuticals, LLCInventors: Preben Houlberg Olesen, Thomas Kruse Hansen, Lise Brown Christiansen, Holger Claus Hansen
-
Patent number: 7507830Abstract: Methods are provided for the construction of unsymmetrical biaryl compounds and alkylated aromatic compounds from arylnitriles using a nickel or palladium catalyzed coupling in which the catalyst has at least one phosphine or phosphite ligand.Type: GrantFiled: September 23, 2004Date of Patent: March 24, 2009Assignee: Pharmacore, Inc.Inventor: Joseph A. Miller
-
Patent number: 7423177Abstract: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, ?-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.Type: GrantFiled: March 5, 2002Date of Patent: September 9, 2008Assignee: TransTech Pharma, Inc.Inventors: Adnan M. M. Mjalli, Robert C. Andrews, Ramesh Gopalaswamy, Chris Wysong
-
Patent number: 7361678Abstract: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, ?-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.Type: GrantFiled: March 5, 2003Date of Patent: April 22, 2008Assignee: TransTech Pharma, Inc.Inventors: Adnan M. M. Mjalli, Robert C. Andrews, Ramesh Gopalaswamy, Anitha Hari, Kwasi S. Avor, Ghassan Qabaja, Xiao-Chuan Guo, Suparna Gupta, David R. Jones, Xin Chen
-
Patent number: 7329684Abstract: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, ?-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.Type: GrantFiled: September 13, 2005Date of Patent: February 12, 2008Assignee: TransTech Pharma, Inc.Inventors: Adnan M. M. Mjalli, Ramesh Gopalaswamy